Effects of low-dose simvastatin on the distribution of plasma cholesterol and oxidized low-density lipoprotein in three ultracentrifugally separated low-density lipoprotein subfractions: 12-month, open-label trial

Journal of Atherosclerosis and Thrombosis

Volumn 17, Issue 10, 2010, Pages 1049-1053

  Homma, Yasuhiko ^a   Michishita, Ichiro ^b   Hayashi, Hiroshi ^c   Shigematsu, Hiroshi ^d  

^a TOKAI UNIVERSITY HOSPITAL   (Japan)

^b Yokohama Municipal Hospital   (Japan)

^c International University of Health and Welfare   (Japan)

^d Sato Clinic   (Japan)

Author keywords

Hs CRP; LDL subfractions; Ox LDL; Plasma lipids; Plasma lipoprotein subfractions; Simvastatin

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDIUM DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG MECHANISM; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LOW DRUG DOSE; MALE; ULTRACENTRIFUGATION;

EID: 78249281015     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.4077     Document Type: Article

References (32)

1. Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet, 1994; 344: 1383-1389
2. Matsuzaki M, Kita T, Mabuchi H, et al: Large scale cohot study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Cir J, 2002; 66: 1087-1095
3. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of anti-oxidant vitamin supplementation in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet, 2002; 360: 7-22
4. Austin MA, Breslow JM, Hennekends CH, Burning JE, Willet WC, Krauss RM: Low-density lipoprotein subclass patterns and the risk of myocardial infarction. JAMA, 1988; 260: 1917-1921
5. Kwiterovich PO: Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. Am J Cardiol, 2002; 90: 30-47
6. Bernis KK, Krauss RM: Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res, 2002; 43: 1364-1379
7. Salonen JT, Herttuala Y, Yamamoto R, et al: Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet, 1992; 339: 883-887
8. Lehtimaki T, Lehtinen S, Solakivi S, et al: Autoantibody against oxidized low-density lipoprotein in patients with angiographically vertified coronary artery disease. Arterioscl Thromb Vasc Biol, 1999; 19: 23-27
9. Holvoet P, Vanhaaecke J, Janssens S, Werf FV, Collen D: Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation, 1998; 98: 1487-1494
10. Ehara S, Ueda M, Naruko T, et al: Elevated levels of oxidized low-density lipoprotein show a positive relation with the severity of acute coronary syndrome. Circulation, 2001; 103: 1955-1960
11. Homma Y: Predictors of atherosclerosis. J Atheroscl Thromb, 2004; 53: 79-88
12. Ishigaki Y, Oka Y, Katagiri H: Circulating oxidized LDL: a biomarker and a pathogenic factor. Curr Opinion Lipidol, 2009; 20: 363-369
13. Sasaki S, Kuwahara N, Kunitomo K, et al: Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia. Am J Cardiol, 2002; 89: 386-389
14. Homma Y, Homma K, Iizuka S, Iigaya K: Effects of fluvastatin on plasma levels of low-density lipoprotein subfractions, oxidized low-density lipoprotein, and soluble adhesion molecules: a twenty-four-weeks, open-label, dose-increasing study. Curr Therapeutic Res, 2003; 64: 236-247
15. De Graaf J, Hendriks JCM, Demacker PNM, Stalenhoef AFH: Enhanced susceptibility to in vitro oxidation of the dense low-density lipoprotein subfraction in healthy subjects. Arterioscl Thromb Vasc Biol, 1991; 11: 298-306
16. Tribble DL, Holl LG, Wood PD, Krauss RM: Variation in oxidative susceptibility among six low-density lipoprotein subfractions of different density and particle size. Atherosclerosis, 1992; 93: 189-199
17. Bahadir MA, Oguz A, Uzunlulu M, Bahadir O: Effects of different statin treatment on small dense low-density lipoprotein in patients with metabolic syndrome. J Atheroscl Thromb, 2009; 16: 684-690
18. Homma Y, Ozawa H, Kobayashi T, Yamaguchu H, Sakane H, Nakamura H: Effects of simvastatin on plasma lipoprotein subfractions, cholesterol esterification rate, and cholesteryl ester transfer protein in type II hyperlipoproteinemia. Atherosclerosis, 1995; 119: 223-234
19. Noma A, Hata Y, Goto Y: Quantification of serum apolipoprotein A-I, A-II, B, C-II, C-III, and E by the turbidimetric immunoassay: reference values, age- and sexrelated differences. Clin Chim Acta, 1993; 221: 147-157
20. Nakajima K, Saito T, Tamura A, et al: Cholesterol in remnant-like lipoproteins in human serum using monoclonal antiapo B-100 and antiapo A-I immunoaffinity mixed gel. Clin Chim Acta, 1993; 223: 53-71
21. Kotani K, Maekawa M, Kanno T, Kondo A, Toda N, Manabe M: Distribution of immuno-reactive malondialdehyde-modified low-density lipoprotein in human serum. Biochim Biophys Acta, 1994; 1215: 121-125
22. Rifai N, Tracy RP, Ridokoker PM: Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem, 1999; 45: 2136-2141
23. Havel RJ, Eder HA, Bragdon JH: The distribution and chemical composition of ultracentrifugally separated lipoproteins in human plasma. J Clin Invest, 1955; 34: 1346-1353
24. Asztalos BF, Horvath KV, McNamara JR, Roheim OS, Rubinstein JJ, Scaefer EJ: Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis, 2002; 164: 361-369
25. Lambertus J, van Tits H, Smilde TJ, et al: Effects of atrovastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia. J Invest Medicine, 2004; 52: 177-184
26. Shames DM, Havel RJ: De novo production of low density lipoproteins: fact or fancy. J Lipid Res, 1991; 32: 1099-1112
27. Packard CJ, Demant T, Stewart JP, et al: Apoprotein B metabolism and distribution of VLDL and LDL subfractions. J Lipid Res, 2000; 41: 305-317
28. Goldstein JL, Brown MS: The LDL receptor. Arterioscl Thromb Vas Biol, 2009; 29: 431-438
29. Jaakkola O, Solakivi T, Yla-Herttuala S, Nikkari T: Receptor mediated binding and degradation of subfractions of human plasma low-density lipoprotein by cultured fibroblasts. BBA, 1989; 1005: 118-122
30. Nigon F, Lesnik P, Rouis M, Chapman MJ: Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res, 1991; 32: 1741-1753
31. Campos H, Arnold KS, Balestra ME, Innerarity TL, Krauss RM: Difference in receptor binding of LDL subfractions. Arterioscl Thromb Vasc Biol, 1996; 16: 794-801
32. Yoshida H, Quehenberger O, Kondratenko N, Green S, Steinberg D: Minimally oxidized low-density lipoprotein increases expression of scavenger receptor A, CD36, and macrosialin in resident mouse peritoneal macrophages. Arterioscl Thromb Vas Biol, 1998; 18: 794-802